Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Price | 1d % | 1w % | 1m % | 3m % | 6m % | 1y % | 3y % | 5y % | 10y % | 52-week High | 52-week Low | % off 52-week High | % off 52-week Low | Beta | Volume | Vol 1d % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRMD | CORMEDIX INC | $12.93 | 2.54% | 25.17% | 13.72% | 10.61% | 21.64% | 169.66% | 213.08% | 167.15% | -9.26% | $17.43 | $4.68 | 25.82% | 176.58% | 0.99 | 2,459,000 | 5.81% |
| TGTX | TG THERAPEUTICS INC | $28.08 | 1.12% | 5.13% | -26.03% | -16.40% | -9.88% | 34.10% | 234.29% | 23.86% | 75.61% | $46.48 | $21.11 | 39.59% | 33.02% | 1.90 | 1,812,000 | 8.63% |
| CORT | CORCEPT THERAPEUTICS INC | $71.75 | -0.35% | -0.77% | 0.47% | -2.20% | -1.18% | 105.34% | 155.59% | 420.65% | 1,209.22% | $117.33 | $33.34 | 38.85% | 115.19% | 0.95 | 693,000 | 27.16% |
| GYRE | GYRE THERAPEUTICS INC | $8.14 | -0.97% | 13.21% | 13.69% | -25.59% | -35.91% | -23.78% | -71.88% | -90.15% | -99.78% | $19.00 | $6.11 | 57.16% | 33.22% | 1.24 | 61,000 | 8.93% |
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $33.38 | 0.30% | 3.83% | 18.83% | 29.03% | 70.74% | 27.55% | 167.90% | 86.48% | N/A | $33.98 | $17.82 | 1.77% | 87.32% | 0.86 | 589,000 | 24.26% |
| KRYS | KRYSTAL BIOTECH INC | $150.27 | -0.04% | 8.37% | 1.72% | 15.30% | -4.10% | -22.53% | 93.75% | 235.05% | N/A | $207.84 | $122.80 | 27.70% | 22.37% | 1.35 | 239,000 | -34.70% |
| HALO | HALOZYME THERAPEUTICS INC | $67.27 | 2.64% | 6.95% | 18.85% | 37.43% | 16.18% | 13.82% | 56.12% | 138.63% | 240.26% | $70.51 | $42.01 | 4.59% | 60.13% | 0.86 | 1,620,000 | 2.73% |
| ARGX | ARGENX SE | $653.83 | 0.21% | -1.21% | 17.60% | 16.39% | 2.32% | 24.56% | 70.78% | 172.83% | N/A | $696.21 | $510.06 | 6.09% | 28.19% | 0.67 | 416,000 | 89.95% |
| RPRX | ROYALTY PHARMA PLC | $36.35 | -0.41% | -3.27% | -0.44% | 9.75% | 10.65% | 32.62% | -17.25% | -20.89% | N/A | $38.00 | $24.05 | 4.34% | 51.14% | 0.52 | 2,937,000 | 1.49% |
| INVA | INNOVIVA INC | $20.92 | 0.19% | 14.07% | 4.81% | 14.13% | 16.03% | 13.63% | 43.68% | 55.19% | 41.73% | $22.00 | $16.67 | 4.91% | 25.49% | 0.47 | 896,000 | -0.55% |
| AUPH | AURINIA PHARMACEUTICALS INC | $12.27 | 1.49% | 7.92% | 36.48% | 50.55% | 53.57% | 119.50% | 42.18% | -14.85% | 241.78% | $12.48 | $6.23 | 1.68% | 96.95% | 1.06 | 2,133,000 | -21.35% |
| VCEL | VERICEL CORP | $36.28 | 1.43% | 0.11% | -2.21% | -12.56% | -36.66% | -21.37% | 18.83% | 123.40% | 986.23% | $63.00 | $33.09 | 42.41% | 9.64% | 1.47 | 655,000 | 47.86% |
| EXEL | EXELIXIS INC | $38.31 | -0.42% | 1.56% | -13.05% | -17.19% | 12.02% | 45.61% | 97.47% | 69.81% | 533.22% | $49.62 | $25.12 | 22.79% | 52.51% | 0.64 | 2,371,000 | 8.71% |
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $36.87 | 0.99% | 7.84% | 5.83% | 7.71% | -5.68% | 4.60% | -27.56% | -0.38% | N/A | $41.61 | $26.47 | 11.39% | 39.29% | 0.85 | 451,000 | 14.76% |
| INCY | INCYTE CORP | $86.92 | 0.88% | 10.88% | 27.36% | 38.50% | 21.96% | 40.92% | 15.46% | -10.91% | -24.15% | $87.06 | $53.56 | 0.16% | 62.29% | 0.59 | 1,884,000 | 2.50% |
| ADMA | ADMA BIOLOGICS INC | $16.99 | 0.12% | 2.85% | -5.51% | -11.51% | 5.07% | -3.41% | 604.98% | 442.81% | 79.79% | $25.67 | $13.50 | 33.81% | 25.85% | 1.13 | 3,109,000 | 30.85% |
| MNKD | MANNKIND CORP | $3.73 | 0.81% | 5.97% | -3.12% | -18.20% | -31.18% | -28.13% | -8.35% | 115.61% | -82.02% | $7.63 | $3.38 | 51.11% | 10.32% | 1.11 | 3,127,000 | 43.97% |
| ATRA | ATARA BIOTHERAPEUTICS INC | $12.29 | 4.86% | 12.19% | 32.58% | 61.50% | 52.10% | 79.94% | -90.79% | -96.06% | -99.02% | $18.71 | $5.01 | 34.30% | 145.55% | 1.85 | 150,000 | 262.32% |
| MDXG | MIMEDX GROUP INC | $7.11 | -0.56% | 1.28% | 12.32% | 0.28% | -13.50% | 13.40% | 70.50% | N/A | -27.52% | $10.14 | $5.47 | 29.88% | 29.98% | 1.21 | 310,000 | -19.90% |
| TECH | BIO-TECHNE CORP | $53.60 | -0.26% | 6.31% | 4.24% | 11.11% | -17.90% | -28.45% | -43.29% | -18.39% | 101.31% | $80.95 | $46.01 | 33.79% | 16.50% | 1.17 | 1,306,000 | -9.37% |
| VCYT | VERACYTE INC | $30.22 | 0.60% | 10.41% | 19.73% | 6.07% | -25.24% | -7.47% | 16.91% | -11.92% | 223.90% | $47.32 | $22.61 | 36.13% | 33.66% | 1.92 | 1,148,000 | -17.53% |
| NVO | NOVO NORDISK A S | $52.41 | 2.87% | 2.60% | -22.03% | -20.77% | -36.34% | -61.90% | -1.46% | 56.78% | 79.24% | $139.74 | $45.05 | 62.49% | 16.34% | 0.61 | 14,495,000 | 22.25% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $57.54 | -0.79% | 0.37% | 1.62% | -1.25% | -11.29% | -35.48% | -40.64% | -51.46% | -58.73% | $94.85 | $52.93 | 39.34% | 8.71% | 0.76 | 2,526,000 | 70.91% |
| NAGE | NIAGEN BIOSCIENCE INC | $10.02 | 3.19% | 2.98% | -9.57% | -4.57% | 69.54% | 204.10% | 469.32% | 94.94% | 167.20% | $14.69 | $3.10 | 31.79% | 223.23% | 1.29 | 868,000 | 19.23% |
| CPRX | CATALYST PHARMACEUTICALS INC | $20.23 | 0.80% | 1.86% | -3.44% | -14.93% | -11.77% | 1.61% | 42.16% | 455.77% | 381.67% | $26.58 | $19.00 | 23.89% | 6.47% | 1.05 | 2,039,000 | 70.06% |
| GMAB | GENMAB A | $23.31 | 1.44% | 8.77% | 10.21% | 18.63% | 7.07% | -14.33% | -37.41% | -37.03% | 148.56% | $27.94 | $17.24 | 16.57% | 35.25% | 0.73 | 1,488,000 | 61.56% |
| VRTX | VERTEX PHARMACEUTICALS INC | $392.79 | 0.64% | 7.16% | -15.38% | -9.57% | -15.00% | -16.78% | 28.56% | 44.78% | 181.35% | $519.88 | $362.50 | 24.45% | 8.36% | 0.60 | 1,409,000 | -17.31% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.